Insulin Assay Standardization: Leading to measures of insulin sensitivity and secretion for practical clinical care by Staten, Myrlene A. et al.
Insulin Assay Standardization
Leading to measures of insulin sensitivity and secretion for practical
clinical care
MYRLENE A. STATEN, MD
1
MICHAEL P. STERN, MD
2
W. GREG MILLER, PHD
3
MICHAEL W. STEFFES, MD, PHD
4
SCOTT E. CAMPBELL, PHD
5
FOR THE INSULIN STANDARDIZATION
WORKGROUP
D
iabetes, primarily type 2 diabetes,
has increased in prevalence
throughout the world and current
projections suggest a continued rise
worldwide for at least the next quarter
century. Insulin resistance, which fre-
quently accompanies obesity, is known
to be a key factor in the pathogenic de-
velopment of type 2 diabetes (1–6).
Type 2 diabetes occurs when insulin se-
cretion is no longer sufﬁcient to com-
pensate for the resistance to the actions
of insulin.
Measurements of insulin sensitivity
and secretion are currently done only for
research purposes and are only compara-
ble in individual studies. There are no
clinical applications for these measures.
In fact, there are no criteria by which an
individual could be classiﬁed as being in-
sulin sensitive or resistant or as having
mild, moderate, or severe impairment of
insulinsecretion.Intheory,onecoulden-
vision that knowledge of an individual’s
responsetoinsulinortheabilitytosecrete
insulin might be useful for selecting pa-
tients for intensiﬁed prevention efforts, in
the choice of initial therapy upon onset of
overt hyperglycemia, or in evaluating the
responsetotherapybeyondglycemia.For
example, if a person newly diagnosed
with diabetes could be determined to be
very insulin resistant, the choice of initial
therapycouldbeadrugthatprimarilyim-
proves insulin sensitivity. On the other
hand, if the person was only moderately
insulin resistant but had more of a defect
in insulin secretion, a drug that improves
insulinsecretionmightbeabetterchoice.
However, these are goals for the future
without current clinical utility.
Oneofthebarriersforconductingthe
extensive research needed to determine
the clinical utility of measures of insulin
sensitivity and secretion is the lack of
standardized insulin assays. Results re-
ported from one study to the next are not
comparable, making only qualitative
comparisons between studies possible.
Larger epidemiology studies have been
limited to populations in which the same
laboratory was used for all measures of
insulin, making it impossible to conduct
any quantitative summarization or meta-
analysis of the results.
The usual progression from research
ﬁndings to clinical guidelines has been
thatinitiallyconsiderableresearchisdone
in intensive studies in small populations,
and epidemiology studies are conducted
withsimplemeasuresthatgeneratehypoth-
eses. Subsequently larger prospective, pop-
ulation-based trials are conducted to
establishclinicaloutcomesanddetermine
the sensitivity and speciﬁcity of outcome
measures to predict clinical status. To
date, only a few trials have investigated
measures of insulin sensitivity and secre-
tion over a period of years in a large num-
ber of individuals to be able to determine
their predictive power. Even when trials
of this type are done, the results are lim-
ited to that speciﬁc insulin assay and are
not translatable to other laboratories or
studies due to the lack of standardization
of insulin assays.
An effort is underway by the Ameri-
can Diabetes Association to standardize
insulin assays so that this barrier to ad-
vancingresearchisremoved.Oncethein-
sulin assays are standardized, research
can be done to establish measures of in-
sulin sensitivity and secretion that can be
used by various research laboratories to
build scientiﬁc consensus on how to de-
ﬁne these measures for use in research. If
the research provides strong evidence for
the ability of measures of insulin sensitiv-
ity and secretion to monitor or predict
clinical outcomes, then experts could be-
gin to draft guidelines for the use of these
measures in the clinical setting.
Reasonably accurate glucose assays
have been available for decades. For insu-
lin, despite the efforts of the previous
workgroup (7), little progress was sus-
tained following that group’s report to
stimulate enhanced harmonization
among both commercial and research as-
says. Thus, substantial work remained to
bring all clinical and research assays into
harmonywithoneanother.CurrentFood
andDrugAdministration–approvedcom-
mercially available assays for insulin pro-
duce a range of values for the same
samples(8,9)basedontheuseofdifferent
insulin standard preparations, variable
protocols, and different approaches for
derivation of reporting units. There
clearly is a need to standardize the refer-
ence system and protocols to enable all
available assays to achieve consistent and
uniform results and to report insulin in
identical units.
The Insulin Standardization Work-
group was established by the American
Diabetes Association in 2004 to address
these issues in conjunction with the Na-
tional Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK), the Cen-
ters for Disease Control and Prevention
(CDC), the European Association for the
Study of Diabetes (EASD), and the Inter-
national Federation of Clinical Chemistry
and Laboratory Medicine (IFCC). The
workgroup submitted recommendations
onthemeasurementofcirculatinginsulin
including the assay speciﬁcity, optimal
type of sample, standardization of the as-
say, and manner of reporting results. The
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The workgroup recommended that
concentrations of insulin be reported in
Systeme Internationale (SI) units: pmol/l,
avoiding all references to traditional insu-
lin units based on insulin biological activ-
ity per milligram of standard preparation.
As insulin preparations have increased in
purity, the original value of 25 units/mg
nolongerapplies.Thehighlypuriﬁed,re-
combinantly produced insulin standards
generously donated to the workgroup
permitted accurate assignment of molar
units of insulin to the calibrators in each
of the participating assays, assuming a
molecularweightofmonomericinsulinof
5,808 Da. In the most recent publication
(11), the Insulin Standardization Work-
group investigated alternative prepara-
tions for insulin reference materials. It
demonstrated an important fact: most as-
says can achieve consistent performance
with calibration traceability based on in-
dividual serum samples with insulin con-
centrations set by isotope dilution mass
spectrometry, a reference measurement
procedure for insulin that greatly im-
provestheassessmentofaccuracyofmea-
surement (12,13). The investigation
showed that not all insulin assays had ac-
ceptable performance characteristics at
concentrations as low as 12 pmol/l (2
U/ml in the old units), which is neces-
sary for clinical use. The workgroup
concluded that several, but not all, com-
mercial assays were able to measure insu-
lin with acceptable precision, accuracy,
and cross-reactivities (11). Reasons for
discrepancies in the results among com-
mercially available assay methods were
likely multifactorial and thus not ex-
plainedbyasingleanalyticalperformance
characteristic. Improvement in standard-
izationofinsulinassayresultswillrequire
anongoingefforttoachievetraceabilityto
the isotope dilution mass spectrometry
high-level reference measurement proce-
dure calibrated with pure recombinant
insulin and for manufacturers to address
immunoassay speciﬁcity and response
characteristics over the measuring inter-
val when necessary (11).
We call for the introduction of a sus-
tainable insulin assay standardization
program. A standardized insulin assay
will encourage research leading to mea-
sures of insulin sensitivity that will be
practicalforclinicalcareinageneralpop-
ulation. Cutoff values of insulin concen-
trations and insulin sensitivity can then
be determined that are associated with
knownmagnitudeofriskfordeveloping
type 2 diabetes. Additional criteria
could be developed, perhaps based on
fasting or stimulated insulin concentra-
tions, which would guide therapy for
type 2 diabetes and assist in conﬁrming
the diagnosis of type 1 diabetes. Insulin
secretion and action are central to the
pathophysiology of diabetes. It is time
to address the chaos in the measures of
these key processes.
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